Evidence map›Paper›PMID 32669656›Full record

Trial reportScientific reports2020

Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20

Bo Jiang, Xiaoyan Ke, Qingyuan Zhang, Wei Xu, Hang Su, Jie Huang, Mingzhi Zhang, Huaqing Wang, Chuan Jin, Jun Zhu and 11 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Biosimilar monoclonal antibodies for cancer treatment in adults.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Bo Jiang *State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Xiaoyan Ke *Hematology Department, Peking University Third Hospital, Beijing, China.
Qingyuan Zhang *Oncology Department, The Affiliated Cancer Hospital of Harbin Medical University, Harbin, China.
Wei XuHematology Department, Jiangsu Province Hospital, Nanjing, China.
Hang SuDepartment of Lymphoma/Head and Neck Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Jie HuangHematology Department, West China Hospital Sichuan University, Chengdu, China.
Mingzhi ZhangOncology Department, The First Affiliated Hospital of Zhengzhou Medical University, Zhengzhou, China.
Huaqing WangOncology Department, Tianjin Union Medical Center Nankai University Affiliated Hospital, Tianjin, China.
Chuan JinForth Medical Department, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China.
Jun ZhuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.
Li LiuHematology Department, Tangdu Hospital, The Medical University of Air Forces, Xi'an, China.
Zhen CaiBone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Xielan ZhaoHematology Department, Xiangya Hospital Central South University, Changsha, China.
Jianfeng ZhouHematology Department, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.
Xiaohong ZhangHematology Department, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Jing LiuHematology Department, The Third Xiangya Hospital of Central South University, Changsha, China.
Hui ZhouInnovent Biologics, Inc., Suzhou, China.
Jie YuInnovent Biologics, Inc., Suzhou, China.
Xing SunInnovent Biologics, Inc., Suzhou, China.
Junyuan QiState Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Lugui QiuState Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. qiulg@ihcams.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This multicenter, randomized, double-blind, parallel-controlled trial aimed to compare the pharmacokinetics (PK) of IBI301 with rituximab in patients with CD20-positive (CD20

Indexed as

AdultAntibodies, MonoclonalAntigens, CD20Antineoplastic Agents, ImmunologicalArea Under CurveBiological AvailabilityBiosimilar PharmaceuticalsB-LymphocytesDouble-Blind MethodFemaleGene ExpressionHumansInjections, IntravenousLymphoma, B-CellMaleMiddle AgedAntibodies, MonoclonalAntigens, CD20Antineoplastic Agents, ImmunologicalBiosimilar PharmaceuticalsRituximab

Identifiers

PMID32669656
PMCPMC7363910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.